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ABSTRACT
Objectives: Although concerns over clinical research
have been expressed, the governance of clinical
research has been little studied. The aim was to
describe research policy, volume, funding and
concerns over clinical research in Finland.
Design: A qualitative study and the data were
collected from various sources, including documents,
statistics and semistructured expert interviews.
Setting: Finland.
Results: We found no national policy for clinical
research. Many actors were responsible for facilitating,
directing, regulating and funding clinical research, but
no actor had the main responsibility. Health
professionals were the main drivers for clinical
research. The role of the health ministry was small.
The ministry distributed state money for clinical
research in health services (EVO-money), but did not
use it to direct research. Municipalities responsible for
health services or national health insurance had little
interest in clinical research. The Academy of Finland
had had initiatives to promote clinical research, but
they had not materialised in funding. Clinical research
was common and internationally competitive, but its
volume had declined relatively in the 2000s. Industry
was an important private funder, mainly supporting
drug trials made for licensing purposes. Drug trials
without an outside sponsor (academic projects)
declined between 2002 and 2010. The funding and its
targeting and amount were no one’s responsibility.
Concerns over clinical research were similar as in other
countries, but it had appeared late.
Conclusions: Our results suggest fragmented
governance and funding in clinical research. The
unsystematic research environment has not prevented
clinical research from flourishing, but the public health
relevance of the research carried out and its
sustainability are unclear.
INTRODUCTION
A strengthening of the scientiﬁc basis of
healthcare has been called for and clinical
research is a key element in achieving this.
Various deﬁnitions and terms have been
used for clinical research. Usually, it is
deﬁned as a subgroup of medical research
and refers to research involving patients as a
whole, with the aim of better diagnosis or
therapy. It usually excludes medical research
using only tissues and other samples, as well
as sociological and psychological research on
patients. However, classiﬁcations of clinical
ARTICLE SUMMARY
Article focus
Using Finland as a case, we
▪ Describe who has responsibility for clinical
research policy, that is, for the direction and
oversight of research activities.
▪ Estimate the volume of clinical research.
▪ Describe who funds clinical research.
▪ Question if there have been any concerns over
the state of clinical research.
Key messages
▪ We found no national policy for clinical research.
Many actors were responsible for facilitating,
directing, regulating and funding clinical research,
but no actor had the main responsibility.
▪ The role of the health ministry was small. The
ministry distributed state money for clinical
research in health services (EVO-money), but did
not use it to direct research. Municipalities
responsible for health services or national health
insurance had little interest in clinical research.
▪ Clinical research was common and internation-
ally competitive, but volume declined relatively in
the 2000s.
▪ Industry was an important private funder, mainly
supporting drug trials made for licensing pur-
poses. Drug trials without an outside sponsor
(academic projects) declined between 2002 and
2010.
▪ Concerns over clinical research were similar as in
other countries, but had appeared late.
Strengths and limitations of this study.
▪ The first study to comprehensively study clinical
research governance in one country using
various methods and data sources.
▪ The number of actors and interest groups is
large, and we did not cover its entirety.
▪ The situation in clinical research is not static and
this study covers only certain time-period (up to
2011).
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research vary according to the source. Also, the concepts
of ‘clinical trials’ (clinical research with an experimental
design) and ‘interventions’ are used variably. Some use
clinical trials to refer to drug trials only.
Academic institutions and researchers in North
America and later in Europe have expressed concerns
over clinical research, with various initiatives attempting
to overcome those problems.1–10 One initiative in
Europe is the network of European academic infrastruc-
tures (ECRIN, The European Clinical Research
Infrastructure Network), which is a part of the European
research infrastructures (ESFRI). Concerns expressed
include the poor availability of medically trained
researchers, a lack of time among clinicians, the low
quality of research, patients not getting the new therap-
ies in a timely fashion, commercial biases in the funding
and conducting of research and the shifting of drug
trials to low income countries. A recent concern is the
regulatory burden placed on clinical research, which is
said to hinder research, especially non-commercial
research.
Clinical trials have ﬂourished within the pharmaceut-
ical ﬁeld, and the drug industry is the main ﬁnancer
and user of trials. Owing to the drug industry’s commer-
cial interests and lobbying power, and in Europe, owing
to the EU mandate, drug trials have garnered special
interest. The European Clinical Trials Directive (in force
since 2004) has been said to make drug trials more difﬁ-
cult and to have decreased the number of trials spon-
sored by non-commercial actors.11–13
Regardless of these common concerns, only few
studies have been published on the governance of clin-
ical research or clinical trials by policy institutions. Here,
policy institutions refers to institutions that are respon-
sible for implementing public research policy, by setting
priorities and aims, granting public research funding
and supporting research networks and training. The
only area covered thus far is publication bias and some
aspects related to the availability of results. We found no
previous published descriptions from Europe about what
is being studied and who are the actors involved. In the
USA, analyses of one type of clinical research—clinical
trials—have been made using a trial register (clinical-
trails.gov).1 14
In this paper, we present the case of Finland: using a
variety of sources we (1) describe the responsibilities
and roles of policy institutions relevant for clinical
research, (2) estimate the volume of clinical research,
(3) describe who funds clinical research and (4) study
any concerns over the state of clinical research. By
research policy, we mean the direction and oversight of
research activities. Such analysis can help to ﬁnd better
ways to advance relevant clinical research.
Study context
Finland is one of the Nordic welfare states, with ample
public services. Its population of about ﬁve million is
homogeneous and well educated. It is an ageing society
and immigration is a new phenomenon. A comparison
of ﬁve European countries (Denmark, Ireland, the
Netherlands, Norway and Switzerland) showed that
funding of research and development (R&D) in general
was high in Finland (3.73% of GNP in 2008), but that
much of it was due to R&D carried out by commercial
enterprises.15 Connections between public and private
research units were more common in Finland than in
the other countries by comparison.15
Finnish healthcare is largely public and is organised by
municipalities, with steering from local politicians. The State
regulates healthcare with laws and guidelines, state subsidies
and retrospective control. Health service funding comes
from a dual system: ﬁrst, an area-based and community-
based tax-funded system covers most of the inpatient care
and much of the outpatient care; second, national health
insurance part subsidises private care, occupational care,
drugs, travel reimbursement and sickness absence costs.
Finland offers signiﬁcant strengths as a clinical
research base, including a well-functioning healthcare
system, a stable homogeneous population, commonly
applied clinical care principles, a good health informa-
tion system with registers, biobanks and lively research
milieus in universities and many hospitals. Clinical
research is regulated by the Medical Research Act of
1999 (modiﬁed in 2010) and various other national and
EU-level laws and directives. All clinical research has to
be considered by either locally based ofﬁcial research
ethics committees (numbering 21 up to 2010) or a
central committee.
METHODS
Data were collected by various methods; the most
important are described below. In addition to these, pre-
sentations in relevant conferences, seminars and meet-
ings and researchers’ previous knowledge of the Finnish
research system were used. Data collection continued till
the end of 2011, with information since then used only
for interpretation.
Documents
Various published reports9 15–23 and internal documents
on research and clinical research made by public bodies
were reviewed; we did not have access to the internal docu-
ments of commercial bodies. Documents were analysed to
identify facts and opinions on the magnitude of clinical
research, its prerequisites, problems and solutions.
Unpublished data from Statistics Finland were
obtained from 2011 to calculate the funding of medical
and clinical research.24 Statistics Finland does not collect
data on the volume of clinical research as a whole (see
table 1 later). The unpaid time of researchers is not
recorded or reported in detail.
Expert interviews
We chose experts by institution. We either used our pre-
vious knowledge to locate the person knowing the
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institution view and/or being knowledgeable on clinical
research governance, or we asked the heads of the insti-
tutions/departments to locate the right persons. At the
end of each interview, we asked further names to be
interviewed (snow-ball method). We approached 26
experts, all of whom agreed to be interviewed. Of them, 15
experts were interviewed face to face and 11 via telephone.
Five were from the Ministry of Social Affairs and Health,
two from the Ministry of Education and Culture and three
from the Finnish Medicines Agency (Fimea); eight were
responsible for research authorisations and/or were from
hospital research units and eight were other experts
(including private healthcare research units). All experts
approached or their substitutes (as recommended by the
target expert) agreed for interview.
Interviews were semistructured and made by two
researchers with medical backgrounds; interviews were
carried out either in Finnish (EH) or English (PV).
A model questionnaire was made, but each interview was
tailored to the interviewee’s position, expertise and inter-
ests. The project and the purpose of the interview (to
obtain the views of experts) were explained and semiconﬁ-
dentiality assured (names not to be used, although where
necessary, the (type) of institute he/she was representing
would be identiﬁed). Respondents talked freely and the
order of the questions in the model questionnaire was not
followed rigidly. The interviews lasted from 30 min to 3 h.
Notes were made during the interview and a summary of
the answers was written down after the interview; the inter-
views were not tape recorded.
The analysis of the published and unpublished docu-
ments and the interview notes focused on identifying
factual statements and opinions related to the roles,
responsibilities and actions of the policy institutions with
regard to clinical research, and to the prerequisites and
problems they experienced to create clinical research.
While not denying the prevalent social science opinion
that such texts and interviewee talk not only reﬂect but
also construct reality, in this study we were closer to the
dominant tradition of the research of history. In that
tradition, the factuality of an observation is strengthened
by repetition of the same observation in different data
sources. Thus, in order to be reported here as a result,
an observation had to be found in similar enough form
in more than one data source, and the factuality of the
observation was not to be undermined by other observa-
tions. The researcher’s own experience of acting as
experts serving some of the policy institutions, that is,
the Academy of Finland and university hospital adminis-
trations was helpful in making interpretations of the
data. Within the family of different qualitative analysis
methods, our method may be called theory-driven quali-
tative content analysis.25
Permissions and ethics
The whole project (MERGO Ethical review and adminis-
trative governance of clinical research) received a posi-
tive statement form the THL ethics committee (17 June
2010, amendment 27 January 2011). The statistics and
Table 1 Estimated research expenses by type of research, place and funder, Finland 2009, million Euros (%)
Place of research Total
State
budget Municipalities
Other
public* Enterprisers†‡ EU Other§
Clinical research
Universities¶ 121 31 2 54 21 5 9
Percentage of university health
research
(42) (30) (48) (51) (55) (27) (43)
Health research**
Universities¶ 287 102 4 105 38 17 20
Other public†† 109 69 5 24 3 6 3
Enterprisers‡‡ 225 – – 9 215 0.3 –
Total 621 171 9 139 255 23 24
All R&D
Universities¶ 1283 996 NA ∼92 ∼197 85 –
Other public 657 431 NA ∼45 ∼148 40 –
Enterprisers 4847 197 NA ∼16 ∼4632 16 –
Total 6787 1624 NA ∼107 ∼4977 141 –
*State+other public.
†Domestic and foreign enterprises.
‡Own funding.
§Domestic and foreign foundations, other foreign, own resources (kotimaiset ja ulkomaiset rahastot, muu ulkomainen, omat varat).
¶Includes universities and universities of applied science; clinical research not specified for other places.
**In universities and other public institutes: medicine and health sciences (lääke- ja terveystieteet); in enterprises: drugs and chemical
products.
††Public sector, social and health ministry.
‡‡Chemical products, drugs (kemialliset tuotteet, lääkeainet).
Source: Statistics Finland (Tilastokeskus 2011).
EU, European Union; R&D, research and development.
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documents used in this paper were public. All interviews
were voluntary.
RESULTS
Responsibility for clinical research policy
Ministry of Health and Social Affairs (hereafter: health minis-
try): based on our interviews and documents, the health
ministry did not consider medical or clinical research
policy to be its core tasks. The content of healthcare or
its evidence base was not felt to be a ministry task, but
rather to be the responsibility of the care providers
themselves or of the educational system (education min-
istry). Public health research (including health services
research) was considered the ministry’s task due to its
research institutes. Still, no person or unit could be
identiﬁed as the focal point. Several people with some-
what diffuse mandates took care of various tasks relating
to research on an ad hoc basis. The vagueness was
reﬂected in the difﬁculty in identifying persons for the
interviews. All the people who were contacted said that
clinical research was not their ﬁeld, but they could not
identify persons whose task it could be. Finally, ﬁve
people in different departments and units were inter-
viewed, none of whom could say that clinical research
policy was their mandate. No governmental institution
exists, such as the National Institute of Clinical
Excellence in the UK, which is tasked with being an
intermediate between clinical research and clinical prac-
tice. The preparation of clinical guidelines was ‘out-
sourced’ to a medical professional association.
However, there were several tasks and structures within
the health ministry directly related to clinical research
policy. They distributed and controlled the state money
for clinical research in health services (EVO-money).
EVO-research money is intended to compensate for
extra research expenditures; the usual hospital costs are
paid by municipalities, which purchase hospital services
for their inhabitants. The health ministry has initiated
many laws, such as on medical research, medicines,
healthcare, data availability and patient rights related to
clinical research. The health ministry had an internal
and an external R&D coordination group (even though
it was relatively inactive at the time of interviews). At the
time of the interviews, the national medical research
ethics committee was within the health ministry (admin-
istratively under the National Advisory Board on Social
Welfare and Health Care Ethics ETENE set by Ministry)
and the ministry granted permissions for research pro-
jects that used healthcare data. Later, the latter two func-
tions have been transferred to institutions operating
under the health ministry.
The health ministry had not used EVO-money for direct-
ing research, that is, to decide which kind of projects or
purposes the money is used for. EVO-money distribution
was considered an administrative task to compensate for
medical research costs, not a mechanism to improve clin-
ical research or healthcare. One civil servant was
responsible for preparing the health ministry’s decision
for distributing the money to the hospital districts, as part
of his many duties. The Ministry of Education and Culture
(hereafter: education ministry) was not consulted in the
use of EVO-money.
A number of proposals have been made for changing
the health ministry’s passive role in the distribution of
EVO-money, but up until 2011, legislation on health ser-
vices had not changed signiﬁcantly. Opposition from the
university hospitals combined with few staff in the health
ministry with personal experience of clinical or health
services research had contributed to the inactivity. The
2011 law stated for the ﬁrst time that the health ministry
has to deﬁne, jointly with the ﬁve university hospitals/
hospital districts, the priority areas and aims of EVO
health research. The health ministry should also oversee
that the areas and aims are followed. However, according
to the interviews, the resources for this task will remain
modest, and so may not allow the ministry to completely
fulﬁl this responsibility.
The health ministry did not collaborate closely with
the other actors in research policy, such as with the edu-
cation ministry, health services or university research
units. Most cooperation had been with the Academy of
Finland, which is an important public research funder
that operates under the education ministry. European
Union (EU) health matters were divided among various
people and departments in the health ministry. The
ministry role in EU research matters was modest at the
time of the interviews; previously, the role used to be
larger.
Ministry of education and culture (education ministry):
Finland does not have a ministry of science, so research
matters were dealt with in various ministries, particularly
within the education ministry and the Ministry of
Employment and Economy (TEM). The education min-
istry had responsibility for academic research and it dis-
tributed state money to universities, polytechnics and
the Academy of Finland (the grant-giving agency). The
education ministry did not take an (open) stand on
research prioritisation. No separate activities on clinical
research could be identiﬁed even though the education
ministry had had some other targeted projects, such as
biotechnology centres. The education ministry oversaw
the education of health professionals (future clinical
researchers), but had not taken particular responsibil-
ities for research activities in healthcare.
The education ministry worked jointly with the
Ministry of Employment and Economy in R&D matters,
particularly in regard to innovations and EU matters.
These two ministries jointly run a research policy body
(TIN, see below).
Ministry of Employment and Economy (TEM) is respon-
sible for the promotion of innovations and EU relations,
jointly with other relevant ministries. An important
public funder (TEKES) operates under this Ministry
(see below). We did not interview TEKES as other inter-
viewees reported that TEM-support was generic and not
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speciﬁcally related to medical or clinical research.
Clinical research had not been a Finnish focus in EU
research matters.
Research and Innovation Council (TIN) is a body under
the prime minister that advises the government on
research and innovation policy. Its Secretariat is divided
between the education ministry and TEM. In recent
years, its focus has been on improvement of the national
economy and technological research. In medicine, bio-
medical research has been an issue, but not clinical
research.
Finnish Medicines Agency (Fimea) (hereafter: drug
agency) has the task of reviewing and approving inter-
ventional research with unlicensed drugs or new indica-
tions (hereafter: drug trials); device and food control is
the responsibility of other government agencies. The
drug agency has interpreted the EU Clinical Trials
Directive broadly to also cover other types of drug
research, such as surveys on drug prescribing and use.
The drug agency itself or other interviewed actors did
not consider its task to be the facilitation of academic
(non-commercial) drug research.
The documents, interviews and observations showed
that the drug agency had a ‘regulatory mind’; ensuring
compliance with national and EU laws and rules were
important, emphasising the drug agency’s key function
of drug control. Even though the interviewed civil ser-
vants were well aware of the concerns over drug trials,
our interpretation was that they had been relatively
passive in ﬁnding solutions both nationally and
internationally.
The drug agency had recognised the problems of non-
commercial drug trials and had noticed their decline in
recent years. They offered simpler procedures for
research with licensed drugs and extra advice for aca-
demic researchers. Academic researchers could also ask
for a waiver of the handling fee. However, it seemed that
the agency considered these as favours on their part and
not a primary duty.
Health services: as municipalities organise and pay for
most health services, they have an interest in the quality
and orientation of the services. But municipality politi-
cians or civil servants did not have an interest in
research, not even when directly relevant to the service
provision. Clinical research has been delegated to other
actors, particularly to the leading physicians in the
healthcare units. A requirement for most leading posi-
tions in public hospitals is academic merit, which has sti-
mulated physicians to do research, even though not
particularly clinical research.
Most university hospitals have clinical research units,
ﬁnanced by overheads from outside grants, EVO-money
(state subsidies) and hospital district support. Clinical
research units have served mainly their own institutes and
protected hospital interests. They could be classiﬁed as
public business brokers or public research contract organi-
sations. The business concept, administrative status and
activity level varied by hospital. The origins were in
contract research with the drug industry, but some units
had broadened into providing many-sided support func-
tions also covering non-commercial research. Clinical
research units were important in facilitating research
administration, but they did not have research policy func-
tions. Their identity was closer to researchers than
research policy makers and their formal and informal con-
nections to the national actors were small.
In the past few years, international and national joint
initiatives and projects have evolved to advance drug
trials in Finland. Even though these initiatives have been
speciﬁcally targeted to drug trials, the suggested mea-
sures are likely to advance clinical research in general,
particularly through better infrastructure. One hospital
district has established jointly with some other bodies a
public company (FinnMedi Research Ltd), which also
ran national activities, such as a network of researchers
on paediatric medicines and FinnTrials (see later
TEKES).
Interviews and documents suggested that clinical—
particularly commercial—research has increasingly
shifted to private healthcare. Some of the largest private
chains have been proactive in helping sponsors and
researchers to ﬁnd each other and they have research
governance ofﬁces with business and law expertise.
Research has been an incentive in recruiting and
keeping physicians in the clinic.
Physician researchers: senior researchers worked as experts
in various functions, and their inﬂuence occurred via
other actors, such as the health ministry, drug agency,
health services research units, various grant-giving bodies
and in international organisations. In addition to these
indirect inﬂuences, physicians’ professional organisations
had established an expert group to solve problems in clin-
ical research,21 23 and various activities to improve condi-
tions, visibility and funding have been proposed since
2010.
There were tight and complex relationships between
university hospitals and university medical schools. An
important lobby for clinical research has been the
medical schools and their Deans. But medical schools
have medical education as their ﬁrst priority. In research
policy, they have remained in the shadow of the biotech-
nology centres attached to the university hospitals and
universities, which have been a priority in regional and
national research and innovation policy.
Volume of clinical research
An international evaluation concluded that the quality
and quantity of Finnish clinical research were high com-
pared with other countries, but the volume was declin-
ing relatively in the 2000s.16 The number of medical
publications per inhabitant was high,16 and Finland
ranked seventh worldwide in the citation analysis of clin-
ical medicine research.16 Vaccination trials and public
health research have been considered special strengths.9
According to a national survey of physicians in 2006,22
a high proportion of physicians reported engagement in
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research (clinical research was not speciﬁed): 46% of
hospital physicians, 20% of private practitioners, 17% of
physicians in occupational care and 13% in public
health centres reported participation in research. The
time frame was not deﬁned, but the question formula-
tion suggested current research. Research was more
common outside the main work than as a part of it.
Surveys of physicians in 2006 and 2011 (unpublished
surveys, TEKES seminars 2011 and 2012) suggested that
in many hospitals and health centres, conditions for
doing clinical research were getting worse, particularly
due to the burden of routine patient care and lack of
time.
In the late 1990s and ﬁrst part of the 2000s, trials with
new drugs were common in Finland (10-fold higher
than expected on the basis of the population size.26
According to the statistics of the national drug agency,
the total number of clinical trials started were relatively
steady from 2001 to 2006 (varying between 238 and 293)
but then declined thereafter (209 in 2010).27 The
largest declines were in the phases 2 and 1 trials. The
trials without an outside sponsor (academic projects)
declined between 2002 and 2010 from about 90 to 40.
There are no ready data on the money or other
resources used in clinical research in Finland.
Furthermore, classiﬁcation and expenditure recording
differ by institutes. Based on the raw data from Statistics
Finland, we constructed table 1, which shows recorded
expenditure by the funder and sector. Clinical research
was speciﬁed only for research in universities, in which it
represented 42% of all health research. Most university
clinical research was funded by the public sector and
only 17% was funded by enterprises. However, when all
health research, including research outside universities
(54% of health research was outside universities), was
included, 41% was funded by enterprises and 36% was
made within enterprises. Compared with all R&D costs
in Finland, health research in enterprises was rarer than
overall (71% of R&D was made within enterprises and
an estimated 73% was funded by enterprises).
A calculation from 1997 to 1998 estimated that of the
expenditure in health research (about EUR 277 mil-
lions), 24% was funded by industry.19 This suggests that
either industry funding for health research has (propor-
tionally) increased, or more likely, that ﬁgures were cal-
culated differently. We found no previous estimates of
funding speciﬁcally of clinical research.
Funding of clinical research
Industry, particularly the drug industry, was an important
private funder, mainly supporting drug trials made for
licencing purposes. We did not ﬁnd any more detailed
public information of industry investment in medical
research than the rough ﬁgures given in table 1.
The health ministry (MOH) distributed to hospital dis-
tricts the state subsidies earmarked for medical research
in public healthcare (EVO-research money). A key
concern brought up by the health ministry, the hospital
districts and researchers was the decline of the subsidy
over the years, both in absolute terms and as purchasing
power. The total amount was about EUR 60 million in
199919 20 and EUR 40 million in 200920 and in 2010.28
The 2011 budget proposed further cuts (to EUR 35
million).
The basic principles for allocating the subsidies were
the same between 1994 (when the system was intro-
duced) and 2010, although the details varied. At the
time of the interviews, subsidies were given to the ﬁve
university hospital districts by the number (and impact
factor of the publication forum) of publications in the
previous year. The university hospital districts distributed
the money based on their own decisions, to be used for
medical and nursing research in their area. Part of the
money was given for infrastructure, part to care units
based on publication activity and part for competing
individual projects. All researchers working in healthcare
within the university hospital area were eligible to apply.
Clinicians considered EVO-money as an important
support for research funding. Money was commonly
used for clinicians’ salaries, enabling them to be free
from clinical work for short time periods, though usually
still working within the same clinic.
The key persons in distributing the money were
leading university professors, but the criteria deciding
body and transparency of the process varied by the uni-
versity hospital. The key criterion, number of previous
publications graded by the type of the publication
forum, was criticised. A problem from the point of view
of clinical research was that the competitiveness of the
strong basic biomedical research, by the EVO criterion,
was much better than that of clinical research.
TEKES (The Finnish Agency for Technology and
Innovation) is under the Ministry of Employment and
Economy (TEM) and was the biggest public funder for
research and innovation. It aimed to promote innova-
tions (mainly commercial) and research that might lead
to innovation, in collaboration with enterprises. It has
supported basic biomedical research aiming for com-
mercial products (biotechnology), telemedicine and
other ICT support for clinical practice, and the develop-
ment of new business models for private clinical service
providers. Support for the building of projects in bio-
technology centres attached to university hospitals was
the main role of TEKES in the biomedical area. Support
for clinical research was marginal.
The 2008–2011 Pharma-programme was established
with the aim of facilitating drug research. It included a
section on clinical trials and as a part of the FinnTrials
project, it aimed to improve the infrastructure for (com-
mercial) clinical research. It aimed to harmonise the
procedures in contract research and other administra-
tion in the ﬁve university hospitals. TEKES also has activ-
ities aimed at locking commercial enterprises into drug
research in Finland.
The Academy of Finland is a grant-giving body under the
education ministry and covers all disciplines. Owing to
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the way the Academy is organised and its experts
chosen,29 the Academy represents the research commu-
nity and not only the ministry. Besides distributing
grants, the Academy has research policy functions. It
produces policy documents for the whole research com-
munity, but its main policy impact is through the
funding it gives. Since the 1990s, the Academy and its
health council have had initiatives to promote clinical
research, including the education of the clinical
researcher.16 Regardless of the various initiatives, it has
not resulted in many extra grants. Clinical research com-
petes for grants with other health research and its com-
petitiveness has not been high with the Academy
criteria. The Academy see its main role as funding basic
research, while clinical research is often categorised as
applied research. Furthermore, while the Academy is
the main funding source for research in social sciences,
humanities and basic (natural) science, its proportion of
funding, and thus impact, for health and technology
research is much lower.
In addition to these main public funders, there were
various other public funders and non-proﬁt foundations
supporting clinical research, mainly through competitive
bids or grants. Their grant volumes, however, were
modest.
Concern over clinical research
Based on our own expert interviews and recent
initiatives by various bodies and published
reports,16–18 20 21 23 30 it was clear that concerns existed
over the magnitude of and circumstances around clin-
ical research. The problems cited were the same as in
other countries: a declining number of clinical research-
ers, difﬁculty in recruiting medical students into
research, modest infrastructure and a lack of non-
commercial funding for clinical research. A particular
concern had been the lack of clinical researchers.
However, the concerns were expressed late and mostly
by researchers or the Academy of Finland. (The most
active discussions seemed to have taken place after our
data collection closing date, December 2011.)
Government bodies other than the Academy of
Finland or TEKES have not acted to promote clinical
research, and concerns over this were not brought up in
our interviews. When probed, some civil servants were
aware of the discussion elsewhere, but clinical research
was not felt to be their mandate or a key problem. This
lack of concern was true even in regard to the health
ministry’s distribution of EVO-research money, which
has declined notably over the years. Finnish public
bodies and researchers have participated in
European-level activities aimed at facilitating clinical
research, but according to the documents and our inter-
views, they have not been the key actors.
Finland is a Nordic country and at the Nordic level,
various initiatives for improving clinical research have
been taken recently,17 18 but none have yet led to con-
crete actions. An initiative of the Nordic Council of
Ministers was to strengthen Nordic multicentre clinical
research and, by extension, also to support national clin-
ical research.17 18 The reasons behind the initiatives
included the usual ones, such as the decline of drug
trials, as well as the need to have more publicly funded
clinical research in the Nordic countries.
None of our interviews or documents showed that the
possible problems caused by commercial actors, particu-
larly the drug industry, in sponsoring clinical research
were being tackled. If it came up, commercial funding
and practices facilitating it were considered important.
DISCUSSION/COMMENTS
Strengths and shortcomings of the study
The situation in regard to research changes constantly.
This applies particularly to clinical research, where solu-
tions for the problems identiﬁed are sought. We aimed
to describe the situation in a single country over the
main period of data collection (2009–early part of
2011), with later changes not included. For example, the
research community as well as physicians associations in
Finland have recently started a public campaign for
more state money (EVO-money) as well as seeking other
improvements to facilitate clinical research.
A problem for our study was how various sources and
actors deﬁned medical and clinical research. Different
people might have had different activities in mind when
considering medical and clinical research. The data and
classiﬁcation of clinical research in statistics were deﬁ-
cient. The classiﬁcation and availability of statistical data
are a problem not only in Finland.31
The number of actors and interest groups in clinical
research is large and we did not cover it in its entirety in
our interviews or document gathering. As the clinical
research policy turned out to be very fragmented, in
hindsight, we could have interviewed experts from more
institutions, such as the Ministry of Employment and
Economy and its research funding arm TEKES, the
Academy of Finland, municipality associations and pro-
fessional associations. However, as the data from differ-
ent sources gave a relatively similar picture, we think
that our ﬁndings give a fair picture of the situation in
Finland at the end of the ﬁrst decade of the millennium.
However, we were not able to articulate all the nuances
or differentiate between personal and institutional views.
Research policy
We found no coordinated national (or regional) policy for
clinical research. Many actors had responsibilities for facili-
tating, directing, regulating and funding clinical research,
but there was no common body or single actor to coordin-
ate the policies of different actors. At the national level,
various ministries were involved, though the role of the
health ministry was passive. In public health services,
municipalities (their political or administrative bodies)
responsible for services had little or no interest in research
policy. Individual health professionals were largely the
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drivers in research matters. Likewise, in the private (and
occupational care) sector, the professionals were the main
actors, while the health insurance body had little interest
in clinical research. Our ﬁndings support a recent recom-
mendation by a professional expert group that improve-
ment of clinical research will require a change in attitude
among health services (municipalities), as research is
claimed to guarantee the quality and efﬁcacy of hospitals
and physicians’ work.21
Our results suggest fragmented governance and funding
of clinical research. They also suggest a lack of strong inter-
est groups, other than the drug industry for drug trials.
Patients or patient advocates were not seen, and although
healthcare organisations gave resources (mainly time),
they did not have a speciﬁc research policy; for govern-
ment and public funders, clinical research was a margina-
lised issue. Only the clinicians were concerned. As such,
the fragmentation of public policies between different
public actors is not speciﬁc to clinical research or research
in general. It is a general tendency in the trend described
as ‘from government to governance’.32 However, in the
case of Finnish clinical research, the new modes of govern-
ance were largely missing.
The fragmentation of governance and funding seems to
be linked to a number of institutional characteristics both
in health services and research policy in Finland. The
decentralised structure and multichannel funding of
health services may prevent a consolidated clinical research
policy by the service system. The institutional fragmenta-
tion of governmental health research policy to at least
three different ministries (Education and Culture,
Employment and Economy and Social Affairs and Health)
may be a second source of fragmentation. A third explan-
ation may be the weak capacity of the clinical researcher
community and the medical faculties to create a common
pressure on the policy makers and institutions to overcome
the fragmentation linked to the competition within the
researcher community for scarce research resources.
Our ﬁnding of a fragmented governance of clinical
research is not likely to be only a Finnish phenomenon.
Various countries are looking for solutions to how best
to target and use limited research resources in an
optimal way.1 33 34 However, an international compara-
tive study of national clinical research policies and policy
institutions would be needed to verify whether Finland
is an exception or an example of a typical situation in
governing and funding clinical research.
Volume and funding
However, international comparisons show good outputs
of research, even though declining recently.16 35 So this
unplanned system has worked (in the past), judging by
the publication and citation numbers. No studies exist,
however, that have compared the societal usefulness and
quality of the research done: were the study questions
relevant to health and were they constructed in a way
that adequately answered the questions posed?
In the USA, the National Institutes of Health are an
important biomedical research funder, including of clin-
ical research2; in Finland, there is no corresponding insti-
tute. Funding for clinical research came from various
sources and was quite fragmented. The drug industry plays
an important role. Otherwise, much seems to be done in
the clinician’s own time and with small-scale funds.
As healthcare organisers and funders did not have a
policy interest in research, the research topics must have
been chosen according to the funders’ and researchers’
own interests. Commercial research is likely to be biased
towards the commercial sale of products.36 Dorman
et al’s37 analysis of trials in acute stroke in 1955–1995
showed that only 12% tested non-drug interventions,
while Tallon et al38 concluded that the research agenda
for osteoarthritis reﬂected the priorities of commercial
funders. Analyses from other countries suggest wastage
in medical research at various stages, including in the
form of studying trivial questions (from a public health
point of view) or leaving results unpublished.34 39
Concern over clinical research
In Finland, public discussion on the state of clinical
research has appeared late, and it has not been particu-
larly visible. State and health service interests have been
low. Statistical data suggest a reduction in the number of
new drug trials in the latter half of the 2000s, and par-
ticularly those without outside sponsorship have
declined. Our own unpublished data from 2002 to 2007
(Hemminki et al, unpublished data 2012) have shown
that the number of clinical research projects is large,
but nevertheless declining.
We conclude that clinical research in Finland has been
strongly active, but is apparently losing some footholds. It
seems to have been researcher based and national or insti-
tutional planning and support is weak. To strengthen clin-
ical research, a better recording of research funding and
activities would be needed to plan actions. A coordinating
institution with responsibility for recording medical/
health research, including clinical research, might help in
identifying problems and alerting to the need for action.
However, the results do not suggest that more rules and
coordination as such, without better resources, would end
in more relevant clinical research.
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